Muscle invasive bladder cancer surgical management has been historically a radical cystoprostatectomy in males and an anterior exenteration in females. Uterine, ovarian, and vaginal preservation are utilized, but raise concerns regarding risk to oncologic control, especially in variant histopathology or advanced stage.
Background: The efficacy of intravesical chemotherapy maintenance for patients with non-muscle invasive bladder cancer (NMIBC) is inferior compared to intravesical bacillus Calmette-Guerin (BCG). How intravesical chemohyperthermia (CHT) compares with BCG is under investigation.
Immune checkpoint inhibitors, FGFR3 inhibitors, and antibody drug-conjugates are recent additions to the armamentarium of agents used to treat advanced urothelial cancer (UC). However, cisplatin-based therapy remains a standard front-line treatment for eligible patients with metastatic UC. Angiogenesis is a critical pathway in UC development and progression. Early-phase clinical trials suggested that targeting angiogenesis could […]
Key Facts Study compares risks of myocarditis, pericarditis and cardiac arrhythmia following a first and second dose of ChAdOx1 (Oxford-AstraZeneca), BNT162b2 mRNA (Pfizer-BioNTech) and RNA-1273 (Moderna) vaccine, and following COVID-19 infection. Study shows increased risk of myocarditis with the first dose of ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) vaccines and the first and second doses of […]
International, multicenter research team develops tool showing prognostic and clinical significance of this recently approved diagnostic imaging modality San Francisco, CA (UroToday.com) — Researchers at UCLA Jonsson Comprehensive Cancer Center led a large international study providing what is believed to be the first evidence (albeit indirect) that a recently approved imaging technique improves risk-stratification and long-term […]
Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) can detect low-volume, nonlocalized (ie, regional or metastatic) prostate cancer that was occult on conventional imaging.
Metabolic syndrome is a long-term complication of systemic chemotherapy for testicular germ cell tumor (TGCT). It is believed to be caused by secondary hypogonadism or toxic medicines because of orchidectomy followed by systemic chemotherapy.
Hereditary papillary renal cell carcinoma (HPRC) is a rare inherited renal cancer syndrome characterized by bilateral and multifocal papillary type 1 renal tumors (PRCC1). Activating germline pathogenic variants of MET gene were identified in HPRC families.
: Pharmacological combinations using immune checkpoint inhibition (ICI), tyrosine kinase inhibition (TKIs) and mammalian target of rapamycin inhibitors (mTOR), have improved survival in metastatic clear cell renal cell cancer (mccRCC).
Radionuclide therapy using the small molecule PSMA bound to the beta-emitting radionuclide, Lutetium-177 (177Lu-PSMA) has demonstrated efficacy and survival benefit castrate resistant metastatic disease and represents a novel new line of therapy.
